We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
Read MoreHide Full Article
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $130.40, marking a -2.42% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.8% for the day. Meanwhile, the Dow lost 0.16%, and the Nasdaq, a tech-heavy index, added 1.63%.
Shares of the HIV and hepatitis C drugmaker witnessed a loss of 2.37% over the previous month, trailing the performance of the Medical sector with its loss of 0.32%, and the S&P 500's gain of 8.11%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company's earnings report is set to go public on May 7, 2026. It is anticipated that the company will report an EPS of $1.89, marking a 4.42% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $6.89 billion, up 3.41% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $8.63 per share and revenue of $30.15 billion, indicating changes of +5.89% and +2.39%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Gilead Sciences. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.32% fall in the Zacks Consensus EPS estimate. Gilead Sciences currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Gilead Sciences has a Forward P/E ratio of 15.48 right now. This valuation marks a discount compared to its industry average Forward P/E of 21.28.
It is also worth noting that GILD currently has a PEG ratio of 1.76. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. GILD's industry had an average PEG ratio of 1.49 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 96, placing it within the top 40% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $130.40, marking a -2.42% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.8% for the day. Meanwhile, the Dow lost 0.16%, and the Nasdaq, a tech-heavy index, added 1.63%.
Shares of the HIV and hepatitis C drugmaker witnessed a loss of 2.37% over the previous month, trailing the performance of the Medical sector with its loss of 0.32%, and the S&P 500's gain of 8.11%.
Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company's earnings report is set to go public on May 7, 2026. It is anticipated that the company will report an EPS of $1.89, marking a 4.42% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $6.89 billion, up 3.41% from the year-ago period.
Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $8.63 per share and revenue of $30.15 billion, indicating changes of +5.89% and +2.39%, respectively, compared to the previous year.
It is also important to note the recent changes to analyst estimates for Gilead Sciences. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 0.32% fall in the Zacks Consensus EPS estimate. Gilead Sciences currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Gilead Sciences has a Forward P/E ratio of 15.48 right now. This valuation marks a discount compared to its industry average Forward P/E of 21.28.
It is also worth noting that GILD currently has a PEG ratio of 1.76. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. GILD's industry had an average PEG ratio of 1.49 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 96, placing it within the top 40% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.